Peter Blume-Jensen - 21 May 2025 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
President and CEO, Director
Signature
/s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen
Issuer symbol
ACRV
Transactions as of
21 May 2025
Net transactions value
-$22,890
Form type
4
Filing time
23 May 2025, 16:58:19 UTC
Previous filing
16 May 2025
Next filing
18 Aug 2025
SEC
View on sec.gov

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
Blume-Jensen Peter President and CEO, Director C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN /s/ Adam D. Levy, Attorney-in-Fact for Peter Blume-Jensen 23 May 2025 0001950499
Masson Kristina EVP - Business Operations, Director C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN /s/ Adam D. Levy, Attorney-in-Fact for Kristina Masson 23 May 2025 0001950501

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability $22,890 -19,904 -0.89% $1.15 2,206,111 21 May 2025 Direct F1, F2
holding ACRV Common Stock 315,686 21 May 2025 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2 These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
F3 These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Remarks:

Exhibit List: Exhibit 24.1 - Power of Attorney for Peter Blume-Jensen; Exhibit 24.2 - Power of Attorney for Kristina Masson